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Background: Patients with follicular lymphoma (FL) have heterogeneous outcomes. 
Predictor models able to distinguish, at diagnosis, patients at high versus low risk of 
progression are still needed.  
Methods: The primary objective of this study was to use gene-expression profiling data to 
build a signature predictive of outcome in patients treated in the rituximab era. In a 
retrospectively assembled training cohort of 134 pretreatment FL patients from the 
prospective randomized PRIMA trial, we developed an expression-based predictor of 
progression-free survival (PFS) that was further evaluated in FFPE samples obtained from 
three independent international cohorts, using NanoString technology. The validation cohorts 
comprised a distinct set of patients from the PRIMA trial (n=178), a cohort from the 
University of Iowa/Mayo Clinic Lymphoma SPORE (n=201) and the Hospital Clinic 
University of Barcelona (n=109). All tissue samples consisted of pretreatment diagnostic 
biopsies and were confirmed as FL grade 1-3a. The patients were all treated with regimens 
containing rituximab and chemotherapy, possibly followed by either rituximab maintenance 
or ibritumomab-tiuxetan consolidation.Findings: The expression levels of 395 genes were 
associated with a risk of progression. Twenty-three genes reflecting both B-cell biology and 
tumor microenvironment were retained to build a predictive model, which identified a 
population at an increased risk of progression (p<0·0001). In a multivariate Cox model for 
PFS adjusted on rituximab maintenance treatment and FLIPI-1, this predictor was found to 
independently predict progression (adjusted hazard ratio (HR) of the high-risk compared to 
the low-risk group: 3·68; 95%CI: 2·19-6·17). The digital gene expression data met quality 
criteria for 460/488 (94%) FFPE samples of the validation cohorts. The predictor 
performances were confirmed in each of the individual validation cohorts (adjusted HR 
[95%CI] comparing high risk to low risk groups were respectively 2·57 [1·65-4·01], 2·12 
[1·32-3·39] and 2·11 [1·01-4·41]). In the combined validation cohort, the median PFS values 
were 3·1 (95%CI: 2·4-2·8) and 10·8 (95%CI: 10·1-NR) years in the high- and low-risk 
groups, respectively. The risk of lymphoma progression at 2 years was twice as high in the 
high-risk group (38% (95%CI: 29-46) versus 19% (95%CI: 15-24)). In a multivariate 
analysis, the score predicted PFS independently of anti-CD20 maintenance treatment and of 
the FLIPI score (hazard ratio for the combined cohort, 2·30; 95%CI, 1·72-3·07).  
 
 6 
Interpretation: We developed a robust 23-gene expression-based predictor of PFS, 
applicable to routinely available FFPE biopsies from FL patients at diagnosis. This score may 
allow individualizing therapy for patients with FL according to the patient risk category. 
Funding: Roche Company, SIRIC Lyric, LYSARC, NIH and the Henry J. Predolin 






Follicular lymphoma (FL) is the most common indolent lymphoma and is characterized by 
prolonged median survival, usually exceeding 10 years.
1
 Treatment options range from 
watchful waiting to CD20-directed immunotherapy alone or in combination with 
chemotherapy.
2
 New non-cytotoxic combinations are also currently being evaluated.
3
 Patient 
outcomes are, however, highly heterogeneous, and a significant proportion of patients are at 
risk of early progression and/or transformation into high-grade lymphoma.
4
 Currently, 
Follicular Lymphoma International Prognostic Index (FLIPI-1 and FLIPI-2) scores are the 
best clinical pre-treatment predictors of outcome, although they are unable to accurately 
capture the group of patients who progress within 2 years.
5-7
 There have also been proposals 
to combine the mutation status of several genes with FLIPI to improve the identification of 
FL patients at high risk of progression.
8,9
 Hence, new predictor models able to distinguish, at 
diagnosis, patients with markedly distinct outcomes are still needed to personalize treatment 
approaches. 
Gene-expression signatures previously reported in FL in the pre-rituximab era have 
highlighted the influence of non-malignant tumor-infiltrating cells.
10
 However, the prognostic 
impact of immune cells in the microenvironment, assessed using immunohistochemistry, has 
remained controversial, potentially due to heterogeneity of patient cohorts, methodologies, 
and statistical endpoints across the studies.
11-14
 Overall, there is still a lack of robust 
confirmatory studies with which to translate these original findings for routine patient 
management. 
We hypothesized that a gene-expression profiling (GEP)-based study, reflecting both the 
tumor biology and microenvironment, would allow building a composite signature predictive 
of outcome in patients treated in the rituximab era. We thus investigated the biological 
features of FL tumors in a retrospective analysis using samples of patients from a large phase 
III trial.
15
 We developed a gene-expression-based predictor of progression-free survival (PFS) 
applicable to formalin-fixed paraffin-embedded (FFPE) tissues, a resource generated during 
routine diagnostic work-up. We validated this predictor model in three distinct, independent 
cohorts of patients, all receiving immunochemotherapy as first-line treatment. Beyond the 
predictor model, we used these data to evaluate gene-expression signatures reflecting different 






Study design and patients 
A gene-expression-based predictor model was produced using a training cohort of FL patients 
and then tested for clinical validation in three independent cohorts (Figure 1). All tissue 
samples (training and all three validation cohorts) consisted of pretreatment diagnostic 
biopsies (obtained within 12 months before treatment initiation) and were confirmed as FL 
grade 1-3a
16
 by expert hematopathologists. This study was conducted in accordance with the 




Fresh-frozen tissue (FFT) tumor biopsies were prospectively obtained from 160 untreated 
patients participating in the phase III randomized PRIMA trial, which evaluated rituximab 
maintenance after rituximab-chemotherapy induction in high-tumor-burden FL patients 
(NCT00140582). In this trial, patients were first treated by one of the three rituximab-
chemotherapy regimens (R-CHOP: rituximab, cyclophosphamide, doxorubicine, vincristine, 
prednisone; R-CVP: rituximab, cyclophosphamide, vincristine, prednisone; R-FCM: 
rituximab, fludarabine, cyclophosphamide, mitoxantrone). After this induction phase, patients 
who obtained a complete or partial response were randomly assigned to observation or 
rituximab maintenance for 2 years (see appendix p 2 for inclusion criteria and design of the 
PRIMA trial).
15
 Response and progression were defined with international standard criteria.
17
 
Patients of the training cohort were French and Belgian patients, exclusively selected based 
on the availability of FFT samples. The clinical characteristics and median follow-up (6·6 
years) of this training cohort were similar to those of patients from the whole PRIMA study 
(appendix p 24). RNA of sufficient quality (RIN>6·5) was obtained for 149/160 cases and 
further processed. FFPE biopsies were also available for 53 of these patients for technical 
validation of gene expression quantification on fixed tissue. 
 
Validation cohorts 
The model generated from the training cohort was further evaluated in three independent 
cohorts of patients for whom FFPE biopsies obtained at diagnosis were available, including a 
distinct validation set from the PRIMA trial (limited to FFPE samples from French and 
Belgian patients of the PRIMA trial who were not part of the training cohort: cohort 1, n=178) 
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and two other sets of newly diagnosed patients, followed in large clinical centers, the 
University of Iowa/Mayo Clinic Lymphoma SPORE
18
 (UIMC, cohort 2, n=201) and the 
Hospital Clinic University of Barcelona (BCN, cohort 3, n=109). Cohorts 2 and 3 consisted of 
newly diagnosed patients who were prospectively recruited in observational studies. They 
were all treated with regimens containing rituximab and chemotherapy, possibly followed by 
either rituximab maintenance or ibritumomab-tiuxetan consolidation and with a median 
follow-up exceeding five years (Table 1). Progression, as identified during routine follow-up 
practices, was defined with similar criteria as in the training cohort. Given that patients having 
received R-chemotherapy in these validation cohorts did not have to fulfill PRIMA trial 
inclusion criteria, their characteristics (including distribution in the different FLIPI categories) 
may differ.  
 
Gene-expression profiling experiments 
Gene-expression profiling was first performed in the training cohort using the Affymetrix 
GeneChip® Human Genome U133 Plus 2.0 array (data available at 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93261). Digital gene expression 
quantification of selected genes was then conducted on RNA from FFPE samples by means of 
NanoString technology, both in some biopsies of the training set (n=53) and in the validation 
cohorts (appendix pp 2,3 for detailed experimental methods). 
 
Statistical analysis 
Predictive model building 
All genes (14,356 probesets representing unique genes and considered expressed above noise 
level, appendix p 4) were tested for association with PFS in the training cohort. As rituximab 
maintenance significantly impacted PFS in the PRIMA trial (appendix p 9), a multivariate 
Cox regression analysis including maintenance treatment as a cofactor was applied to the 134 
randomized patients. Initial clinical features (such as FLIPI score) were not included in the 
model, in order to design a fully biologically based model. P-values were adjusted for 
multiple testing, and only genes significant at the False Discovery Rate (FDR) threshold of 
5% were retained. Of the 395 genes whose expression was significantly associated with PFS, 
we selected an initial set of 95 genes (see appendix pp 4, 10 for selection criteria). The 
expression levels of these 95 manually curated genes and four housekeeping genes were then 
measured using NanoString in a subset of 53 FFPE samples from the training cohort to assess 
the technical replication between the two technologies. Genes with a correlation coefficient 
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>0·75 were retained in an L2-penalized (Ridge) Cox model adjusted for rituximab 
maintenance to build a multigene score predicting PFS independently of the effect of the 
maintenance treatment. The choice of Ridge penalization was guided by the multicollinearity 
between the predictors. The global performance of the model was determined by means of the 
concordance statistic (C-statistic).
19
 An optimal threshold on the score to separate patients 
into low- and high-risk groups was determined using the MaxStat package
20
 to select the 
cutoff value producing the maximal log-rank score in the training cohort. 
The locked model, including the multigene score and the threshold, was first evaluated in the 
three validation groups separately. The three groups were subsequently pooled for additional 
analyses. Sensitivity and specificity of the score for the prediction of the risk of lymphoma 
progression at two years were assessed on the combined validation cohorts (appendix p 6). 
All statistical analyses, model training and testing were conducted using R. Detailed 
descriptions on statistical methods are provided in the appendix p 4. 
Unsupervised clustering and functional enrichment analyses 
Gene clustering was performed on microarray expression data from the training cohort by 
means of an independent component analysis (ICA).
21 
In contrast with PFS-supervised 
analysis, this unsupervised analysis was performed on all patients from the training cohort 
(n=148 passing QC). Briefly, ICA identifies expression signatures (“components”) capturing 
major underlying sources of variation in the data. Permutations were applied to determine the 
maximal number of non-random components. For each component, the most influential 
genes, i.e. those with highest weights (“leading genes”) were retrieved using a standard 
deviation threshold of 3. To infer the potential biological relevance of ICA components, we 
compared their leading genes with gene sets of the Molecular Signature Database (MSigDB) 
v5.0 and Leukemia/Lymphoma Molecular Profiling Project (LLMPP) collections 
(SignatureDB)
22
 (appendix p 5). 
 
Role of the funding source  
The funding sources had no involvement in study design, collection, analysis, and 
interpretation of the data, and in writing of the report or decision to submit this paper for 
publication. SHu, BT, JPJ, ET, MC, SB, AV, and GS had access to the raw Affymetrix 
microarray expression data. SHu, BT, JPJ, BA, CR, DG, and GS had access to the raw 
Nanostring data. The LYSARC (Lymphoma Study Academic Research organisation) 
provided access to raw clinical data of PRIMA patients to SHu, BT, JPJ, CH, PF, HT, PB, FJ, 
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and GS. LM, ALG and EC had access to raw clinical data of BCN patients. ALF, SMA, BKL, 
FO, and JRC had access to raw clinical data of UIMC patients. BT and JPJ conducted the 
final bioinformatics and statistical analyses. The corresponding author had full access to all 





Predictive model of progression-free survival 
In the PFS-supervised analysis, differential expression of 395 genes (list in appendix p 24) 
was significantly associated with outcome in the training cohort. Higher expression levels 
were associated with longer PFS for 228 genes and with shorter PFS for 167 genes (appendix 
p 11). Of those 395 genes, 95 were selected by manually curating for each gene to integrate 
technical, statistical and biological aspects. To build a PFS predictive model applicable to 
FFPE samples, the expression of those 95 curated genes was measured using NanoString 
technology on 53 FFPE tissues derived from the same biopsies as in the training set. Twenty-
three genes with correlation coefficients >0·75 between the two technologies and sample 
types (microarray on FFT versus NanoString on FFPE samples) were retained (appendix p 
12). This panel included genes previously described to be involved in B-cell development 
(VPREB1, FOXO1, FCRL2, AFF3, TCF4), apoptosis, and DNA damage response (RASSF6, 
GADD45A), cell cycle (E2F5, USP44), cell migration (CXCR4, SEMA4B, EML6, DCAF12, 
VCL, RGS10), immune regulation (CXCR4, KIAA0040, TAGAP, ORAI2, KIAA0040, 
METRNL), and other processes (PRDM15, ABCB1, ALDH2, SHISA8) although some of these 
genes are involved in multiple additional pathways.  
The 23-gene expression signature scores ranged from 0·621 to 1·504 in the training cohort. 
The C-statistic was 0·709 (95% confidence interval [CI]: 0·644-0·773), outperforming FLIPI-
1 (0·578, 95%CI: 0·501-0·655). A score of 1·075 was determined as the optimal threshold 
(appendix p 13) to separate patients into high- (n=47, 35%) and low-risk (n=87, 65%) groups 
(p<0·0001, log-rank test) (Figure 2). In a multivariate Cox model for PFS adjusted on 
rituximab maintenance treatment and FLIPI-1, this predictor was found to independently 
predict progression (adjusted hazard ratio (HR) of the high-risk compared to the low-risk 
group: 3·68; 95%CI: 2·19-6·17; p<0·0001). The 5-year PFS rates were 26% (95%CI: 16-43) 
and 73% (95%CI: 64-83) for the high- and low-risk groups, respectively. Gene coefficients 
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and score thresholds allowing score calculation from either Affymetrix or Nanostring values 
are given in appendix p 44.  
 
Validation of the model in independent cohorts  
The 23-gene expression model was then tested in three independent cohorts (Figure 3). The 
digital gene expression data met quality criteria for 460/488 FFPE samples, achieving an 
overall success rate of 94%, with similar performances across the three cohorts (cohort 1: 
172/178, 97%; cohort 2:186/201, 93%; cohort 3: 102/109, 94%). When the model was first 
assessed separately in each cohort, similar performances to those obtained in the training 
cohort were observed, with C-statistic values of 0·650 (95%CI: 0·587-0·712), 0·619 (95%CI: 
0·558-0·681) and 0·614 (95%CI: 0·509-0·720) in cohorts 1, 2, and 3, respectively. The score 
threshold applied the high-risk group classification to 34% (59/172, cohort 1), 23% (42/186, 
cohort 2), and 21% (21/102, cohort 3) of patients, and all these groups had a significantly 
worse outcome than their low-risk counterparts (Figure 4A-C). In a multivariate Cox model 
adjusted on maintenance treatment and FLIPI-1, the score was an independent predictor of 
PFS in each validation cohort (adjusted HR [95%CI] comparing high risk to low risk groups: 
cohort 1, 2·57 [1·65-4·01]; cohort 2, 2·12 [1·32-3·39]; cohort 3, 2·11 [1·01-4·41]).  
These results allowed us to pool the three cohorts for a combined analysis (n=460, median 
follow-up of the combined cohort: 6·6 years, IQR: 4·9-7·2). The C-statistic in the combined 
cohort was 0·628 (95%CI: 0·587-0·668), showing similar performances to FLIPI (n=453 
patients evaluable, C-statistic 0·621, 95%CI: 0·583-0·659; appendix p 14). The median PFS 
values of the overall validation cohort were 3·1 (95%CI: 2·4-4·8) and 10·8 (95%CI: 10·1-not 
reached) years in the high- and low-risk groups, respectively (p<0·0001) (Figure 4D). The 
prognostic impact of the predictor was maintained in each group of induction chemotherapy 
(appendix p 15). 
Early relapse within 2 years after diagnosis (POD24) has recently been shown to define a 
group of patients at high risk of death.
7
 We confirmed the impact of POD24 status on overall 
survival in the combined validation cohort (n=438 patients evaluable, appendix p 16). As the 
POD24 is not defined at the time of diagnosis, it is of critical importance to identify, as soon 
as the time of diagnosis, the patients who will experience early progression. In the combined 
validation cohort, the 2-year progression rate was 19% (95%CI: 15%-24%) in patients with a 
low predictor score (low-risk group) but rose to 38% (95%CI: 29%-46%) in patients with a 
high predictor score (high-risk group), showing the model’s ability to predict early relapse. 
The score predicted POD24 with a sensitivity of 43% and a specificity of 79%, resulting 
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respectively in positive predictive value of 38% and a negative predictive value of 82%. 
However, this signature score was not associated with either OS from the time of diagnosis 
(appendix p 17) or lymphoma-specific survival (appendix p 18).  
Patients in the high-risk group presented with a significantly higher frequency of B-
symptoms, bone marrow involvement, and Ann Arbor stages III-IV as well as higher FLIPI 
scores but were also significantly younger and had lower histological grades (Table 2). The 
score predicted PFS in the combined cohort independently of maintenance treatment and 
FLIPI-1 score (adjusted HR of the high-risk compared to the low-risk group: 2·30 [1·72-
3·07]). When the patients were grouped according to their FLIPI-1 risk category, the score 
significantly predicted PFS in all subgroups (Figure 4E-G and Table 3). In particular, the 
model stratified patients with high-risk FLIPI into groups differing by more than four years in 
median PFS (2·1 versus 6·6 years) and 50% of those with high-risk FLIPI and high-risk score 
experienced progression within two years, thus meeting criteria of high risk of early death by 
POD24.  
 
The biological basis and prognostic significance of gene-expression signatures 
Expression data previously generated from FL tumors and reactive lymph nodes or tonsils
23
 
were used as an appraisal for evaluating which cell types (lymphoma cells and/or tumor 
microenvironment) expressed the 23 genes included in the model (appendix p 19).  Most 
genes were more highly expressed in B cells compared to the microenvironment (except for 
GADD45A, ABCB1, RGS10). A differential intensity of expression between tumor and non-
tumor B cells was observed for a few genes whose expression was associated with either 
longer (ABCB1, SHISA8, ALDH2, VCL) or shorter (FOXO1, PRDM15, EML6, SEMA4B) time 
to progression. 
As a previous GEP study reported a negative impact of the macrophage part on outcome in 
patients treated in the pre-rituximab era,
10
 we then evaluated the previously described IR1 (T-
cells and macrophages signature) and IR2 (macrophages and dendritic cells) signatures in the  
training cohort (n=134 randomized patients, appendix p 4).  When combined into a composite 
score using the weights specified as originally described, this score did not predict PFS in our 
series. When evaluated separately, both signatures were associated with a longer PFS (IR1: 
p=0·0056, IR2: p=0·0018, log-rank test; appendix p 20).  
To further investigate the biological basis of expression patterns acting in FL tumors, we 
performed an exploratory unsupervised analysis of the gene-expression data generated in the 
training cohort (including randomized and non-randomized patients, n=148) using 
 
 14 
independent component analysis (ICA). After discarding those potentially associated with 
experimental batches (appendix p 5), we identified 19 independent gene signatures (appendix 
p 21). One of these signatures, ICA13, was highly associated with patient outcomes, patients 
with a high ICA13 score (ie, higher expression of the main genes contributing to ICA13 
signature, appendix p 45) having a shorter PFS (p=0·00091) (appendix p 21). It comprised 
genes expressed by germinal-center (GC) B-cells such as AICDA, BACH2, TCF4, ORAI2, 
E2F5, CXCR4 or POU2AF1 (appendix p 45). A significant overlap was observed between 
leading genes of this component (n=133) and the 167 bad-prognosis genes in the initial 
supervised analysis (24 genes in overlap indicated in appendix p 45, p<0·0001). This ICA13 
was also highly correlated with our 23-gene predictor score (p<0·0001;appendix p 21). 
Enrichment analyses revealed that this signature also overlapped with B-cell progenitor 
signatures as well as with genes overexpressed in Burkitt lymphoma compared to diffuse 
large B-cell lymphoma (DLBCL) (appendix p 46). Comparison with other datasets obtained 
from normal and malignant B-cell subsets (appendix p 7) showed that ICA13 was highly 
expressed in centroblasts located in the GC dark zone and was particularly enriched in Burkitt 
lymphomas and, to a lesser extent, in normal pre-B cells (appendix p 22).  
 
Discussion 
We have developed a gene-expression-based predictor of PFS in high-tumor-burden FL that 
identifies, at diagnosis, those patients who have an increased risk of progression when treated 
initially with rituximab-chemotherapy. The model was tested in three independent cohorts of 
patients, where it confirmed its ability to accurately identify a high-risk population 
independently of the FLIPI score and maintenance by rituximab. These results argue that our 
model relies on biologically relevant features of tumor cells involved in disease progression, 
and not merely associates with known clinical predictors. The proportion of high-risk patients 
slightly differed between the validation cohorts (34%, 23%, and 21% of patients in cohorts 1, 
2, and 3, respectively), which might be explained by the specific selection for high-tumor 
burden patients in the PRIMA trial.  
The predictor was developed to be used on the NanoString platform,
24
 which enables accurate 
and reproducible quantification of RNA obtained from FFPE samples
25
 (or even on core 
biopsies). The NanoString platform is now present in many clinical laboratories that can apply 
the score calculation exactly as described in our manuscript. Despite the variable geographic 
origin and the age of FFPE blocks used in this study, sufficient quality of gene expression was 
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obtained in 94% of samples, confirming that this technology represents a promising option for 
a gene-expression-based clinical test.  
In our study, the genes of the 23-gene model were selected based on several experimental 
criteria, but were also manually curated for their biologic significance, which could introduce 
potential bias. Nevertheless, our process identified a robust model that was externally 
validated. Limitations of our study include the lack of patients having received bendamustine-
rituximab, and the fact the 23-gene model could not predict patients overall survival or the 
risk of transformation, given the few events observed in those cohorts. Another validation 
cohort would also have been helpful to confirm the unsupervised clustering analyses, but 
those were exploratory to investigate potential links between lymphoma biology and the 
predictive model. Furthermore, while it reflects multiple aspects of the biology of the tumor 
including lymphoma cells as well as their microenvironment, it would be premature to use its 
results in order to identify patients with specific biological characteristics that would benefit 
from particular targeted therapies. Finally, spatial heterogeneity has been shown to greatly 
influence mutation detection in FL. It is uncertain whether the same limitation would be 
observed with gene-expression profiling of the tumors. 
 
Other predictors of FL outcome have been recently proposed that combine mutation data with 
FLIPI,
8,9
 and our score showed similar performances (sensitivity, specificity, positive and 
negative predictive values) to predict PFS or POD24.
9
 Although the GEP-based predictor 
might be combined together with gene mutations to improve patient stratification, we aimed 
at using a single and highly reproducible technique that would be easily applied in the clinical 
setting. 
Outcome prediction by gene-expression signatures has been previously reported in FL in the 
pre-rituximab era by the LLMPP, which emphasized the role of non-malignant tumor-
infiltrating cells. When applying the LLMPP algorithm
10
 in our training cohort, we found that 
both IR1 and IR2 signatures were associated with longer PFS. The lack of association of the 
IR2 signature with a poor outcome here is in agreement with immunohistochemistry studies 
performed in the rituximab era.
14,26,27
 The correlation of macrophage infiltration with patients 
prognosis is still controversial, but may vary according to the use of rituximab or different 
chemotherapeutic regimens.
14
 In particular, it has been recently suggested that doxorubicin-
containing regimen may abrogate the negative impact of CD163+ TAMs.
14 
 
We also investigated the biological processes acting in FL tumors at diagnosis using an 
unsupervised analysis. We identified in an exploratory analysis a gene signature (ICA13) that 
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was strongly associated with poor prognosis. Although the two analyses were performed 
independently, nine out of the 23 genes retained in the predictor (CXCR4, DCAF12, E2F5, 
ORAI2, PRDM15, RASSF6, TAGAP, TCF4, USP44) were part of the ICA13 signature whose 
score was highly correlated with our predictor. We also observed that some of the 23 genes 
had a distinct expression pattern between FL tumor B-cells and normal B-cells. Altogether, 
these data support that our 23-gene expression-based model recovers biologically meaningful 
attributes of lymphoma cells that are truly associated with the risk of disease progression. The 
ICA13 component revealed characteristics of “Burkitt-like” cells and/or dark zone 
centroblastes and/or immature pre-B cells. Although some progenitor-like transcriptional 
programs might be reactivated within GC during normal B-cell development, the adverse 
prognostic significance of such signature in FL is provocative, as is the strong negative 
impact of the expression of the surrogate light chain VPREB1 transcript. An Embryonic Stem 
Cell-like transcriptional program underlying histological transformation was described in FL 
patients,
28
 and the expression of the surrogate light chains was observed in some FL cases that 
transformed into B-lymphoblastic lymphomas.
29
 Altogether, one might hypothesize that (i) a 
subset of FL cells could arise from self-renewing ancestral cells and retain a partially active 
progenitor-like expression program, or may reacquire such program following re-entry cycles 
in the GC;
30
 and (ii) such features, also reminiscent of Burkitt cells and/or progenitor B cells, 
are related to disease aggressiveness in a subset of patients. 
In conclusion, we have established a 23-gene predictive score able to identify in routine 
practice two groups of patients with FL with markedly distinct outcomes when treated with 
immunochemotherapy. This predictor captures multiple aspects of the biology of the tumor 
and the heterogeneous composition of its microenvironment. Together with clinical 
parameters such as the FLIPI index, this score may already allow to better adjust current 
therapeutic options according to the patient risk category. For patients at low risk of 
progression, shorter treatments and with a low toxicity profile should be considered. For 
patients with high-risk FLIPI and a high 23-gene score, having a 50% risk estimate of 
lymphoma progression at 2 years, new options should be developed. This group represents an 
ideal target population to investigate innovative combinations aiming to improve their 
outcome. Further studies are required to determine whether this model is valid in low-tumor-
burden patients (currently managed with watchful waiting or single-agent rituximab) and in 
patients treated with novel agents that may interfere both with tumor B-cells and with their 
microenvironment.
12
 This 23-gene predictor may thus represent a promising tool to further 
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Table and figure legends 
 
Table 1: Demographics and clinical characteristics of patients in the training cohort and 
the three validation cohorts. 
The results obtained from the training set were further validated in three independent cohorts 
of patients drawn from a distinct validation set in the PRIMA study (cohort 1), the University 
of Iowa/Mayo Clinic Lymphoma SPORE (cohort 2) and the Hospital Clinic University of 
Barcelona (cohort 3).  
*Because of rounding, percentages may not total 100.  
**Undetermined/other included FL of undetermined grade (except 3b), FL with a very small 
component of DLBCL<10% and FL with diffuse area. 
Abbreviations: BM, bone marrow; LDH, lactate dehydrogenase; R, rituximab; CHOP, 
cyclophosphamide, doxorubicin, vincristine, prednisone; CVP, cyclophosphamide, 
vincristine, prednisone; FCM, fludarabine, cyclophosphamide, mitoxantrone; NR, not 
reached.  
 
Table 2: Patient characteristics according to the prognostic group defined by the gene-
expression predictor.  
Clinical and treatment characteristics were compared using Fisher’s exact test. 
*Because of rounding, percentages may not total 100.  
**Undetermined/other included FL of undetermined grade (except 3B, n=16), FL with 
component DLBCL<10% (n=10) and FL with diffuse area (n=2). 
 
Table 3: Progression-free survival according to the predictor score, in each validation 
cohort and in FLIPI risk categories. 
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Median PFS, 2-year and 5-year PFS values are indicated for each validation cohort and each 
FLIPI subgroup. Hazard ratios were calculated in a multivariate Cox model adjusted on 
rituximab maintenance treatment and FLIPI-1 in each validation cohort. The multivariate Cox 
model was applied to 171, 186 and 96 patients of cohorts 1, 2 and 3, respectively, because 
information regarding FLIPI was missing for some patients. In the combined cohort, the 
model was thus applied to 453 patients with FLIPI scores. In FLIPI subgroups, a univariate 
Cox model was applied. Abbreviations: HR: hazard ratio; PFS: progression-free survival; 
95%CI: 95% confidence interval. 
 
Figure 1: Outline of the overall study design.  
Fresh-frozen tissue (FFT) tumor biopsies were prospectively obtained from 160 untreated 
patients enrolled in the international PRIMA trial. RNA with sufficient quality (RIN>6·5) was 
obtained for 149/160 cases and gene-expression profiling was performed using Affymetrix 
U133 Plus 2.0 micro-arrays. A multivariate Cox regression analysis identified genes whose 
expression was associated with PFS independent of maintenance treatment in the subgroup of 
randomized patients. Expression levels from 95 curated genes were then determined by means 
of digital expression profiling (NanoString technology) in 53 FFPET samples of the training 
set, allowing assessment of the technical replication of expression levels for each gene 
between technologies. Genes with high correlation (>0·75) were included in a L2-penalized 
Cox model adjusted on rituximab maintenance to build a PFS-predictive score. The model 
was further evaluated using NanoString technology in 488 FFPET samples from 3 
independent international cohorts of patients: a distinct validation set from the PRIMA trial 
(n=178), and two others obtained in large centers (respectively the Mayo Clinic/Iowa SPORE 
project, n=201 and the Barcelona Hospital Clinic, n=109). An unsupervised analysis of the 
gene-expression data generated in the training cohort was also performed independently. 
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Abbreviations: FFT: fresh-frozen tissues; FFPE: formalin-fixed paraffin-embedded tissues; 
PFS: progression-free survival. 
 
Figure 2: Progression-free survival of patients from the training cohort, according to the 
predictor score. 
Kaplan-Meier estimates of progression-free survival in randomized patients of the training 
cohort, since the time of randomization in PRIMA trial. An optimal threshold was set to 
separate patients into high- (n=47, 35% of the patients, red curve) and low-risk (n=87, 65% of 
the patients, blue curve) groups with significantly different outcomes (p<0·0001, log rank 
test). The 5-year PFS rates were 26% (95%CI: 16-43) and 73% (95%CI: 64-83) for the high- 
and low-risk groups, respectively. For each time point the number of patients at risk and 
(number of patients censored) are indicated. 
Abbreviations: PFS: progression-free survival. 
 
Figure 3: The gene expression-based predictor for FL patients tested in the validation 
cohorts.  
The predictor is a linear combination of the log2-transformed normalized gene expression 
levels weighted by individual gene coefficients. A: The relative gene expression levels of the 
23 genes in the predictive model are presented in the form of a heat map. Each column 
represents a single patient from the combined validation cohorts, arranged according to the 
predictor score, with lowest score on the left. Each row represents a gene from the model, 
ordered by gene contribution to the score. B: The score from the predictor for patients in the 
validation cohorts. The patients are arranged as in panel A. The vertical red line separates 
patients into high- (n=122, 27% of the patients) and low-risk (n=338, 73% of the patients) 
groups according to the threshold (horizontal line) determined in the training cohort. The 
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clinical and treatment characteristics of the patients are depicted. Cohort 1 included patients 
from the PRIMA trial, cohort 2 from the University of Iowa/Mayo Clinic Lymphoma SPORE 
and cohort 3 from the Hospital Clinic University of Barcelona. C: The relative contributions 
of each of the 23 genes to score variation . The X axis position of the boxes represents the 
absolute average contribution of the genes (calculated as the mean expression in a given 
cohort, multiplied by the coefficient assigned to the gene in the score). The width of the boxes 
shows the contribution of each gene to the score variation (calculated as the standard 
deviation of the gene in the cohort multiplied by its coefficient). Gene contributions are 
presented in both the training cohort (grey) and the combined validation cohort (black). 
 
Figure 4: Kaplan-Meier estimates of progression-free survival predicted by the 23-gene 
signature score among patients of the three validation cohorts and according to FLIPI 
score.  
The threshold set in the training cohort separated patients into high- and low-risk groups (red 
and blue curves, respectively). The 23-gene score significantly predicted PFS in patients from 
each validation cohort (A-C: Cohort 1, 2, and 3, respectively) as well as in the combined 
validation cohorts (D) and in each FLIPI subgroup (E-G: low, intermediate and high risk 
FLIPI scores, respectively). Logrank test p-values for each of the comparisons are reported. 
FLIPI score was available for 453 patients. Abbreviations: PFS: progression-free survival; 








Research in context  
 
Evidence before this study  
We searched PubMed on August 15, 2017, with no date restrictions, for all original 
publications (ie, review articles were excluded) with the search terms “follicular lymphoma” 
in the title, “gene expression OR expression signature” in the title or abstract, and “prognosis 
OR prognostic OR prediction OR predictive OR progression OR risk OR transformation OR 
survival” anywhere in the text. This search identified a total of 52 original publications. The 
relevant publications addressing the impact of gene expression on outcome in FL patients 
were of two types: some studies used transcriptome-wide profiling to identify signatures 
predictive of progression, death or histologic transformation, whereas others focused on 
somatic alterations in single genes, impacting the global transcriptional profile and outcome.  
The seminal LLMPP study highlighted the role of non-malignant tumor-infiltrating cells on 
FL prognosis in the pre-rituximab era, enabling to build a molecular predictor of overall 
survival, based on two expression signatures of immune response (IR1 and IR2).  Another 
study identified a T-cell signature of favorable prognosis and a proliferation signature 
associated with relapse. Other groups, using RT-PCR and/or immunohistochemistry to assess 
the expression levels of single genes, confirmed the influence of different immune subsets on 
the risk of disease progression or death, but sometimes with conflicting results and in 
heterogeneously treated patient cohorts.  
Several other studies focused on molecular alterations driving histologic transformation. One 
study identified the role of an embryonic stem cell signature probably sustained by MYC 
activation in tFL. Another one pinpointed 6 signatures related to the NF-kB pathway, with 
high scores found in biopsies preceding transformation, although not necessarily detected at 
the time of diagnosis.  
Finally, other studies identified the clinical significance of somatic alterations and/or 
expression pattern in single genes. Although not directly linked to our gene expression-
focused search, new clinico-genetic predictors (m7-FLIPI and POD24-PI), combining the 
mutation status of several genes with the FLIPI score, have been proposed to improve the 




Added value of this study  
To overcome the limitations of previous studies due to heterogeneous treatment cohorts, small 
size and/or no validation cohorts, we conducted a progression-free survival (PFS)-supervised 
analysis on expression data obtained in a large cohort of patients in the setting of a clinical 
trial. Our study identified a 23-gene score able to predict the risk of progression in FL patients 
at diagnosis, independently of the FLIPI score and use of anti-CD20 maintenance therapy. 
Importantly, we developed this predictor to be fully applicable to routinely available 
formalin-fixed, paraffin-embedded biopsies. Moreover, results were further validated in 3 
independent international cohorts of patients homogeneously treated with 
immunochemotherapy. To the best of our knowledge, this is the largest study to date of gene-
expression profiling able to predict the risk of progression of FL patients receiving first-line 
immunochemotherapy, confirmed in 3 independent cohorts. Furthermore, our study identified 
a gene signature characteristic of B-cell centroblasts that was prognostic, underlining that 
beside tumor microenvironment, tumor B-cell biology itself contributed to the clinical 
aggressiveness of the disease. 
Implications of all the available evidence  
Despite recent progress in the stratification and management of FL patients, a significant 
proportion are still underserved by current standard treatment and experience rapid 
progression of their disease. Our gene-expression predictor could be of valuable interest in the 
clinical setting to identify patients at high-risk but also low-risk of progression and 
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Cohort Training cohort Validation cohort 1 Validation cohort 2 Validation cohort 3 
Number of patients N=134 N=172 N=186 N=102 
  no./total no. (%)* no./total no. (%)* no./total no. (%)* no./total no. (%)* 
Follow-up duration          
median, IQR (yrs) 6.6 (6.0-7.0) 6.8 (6.5-7.1) 5.5 (3.9-7.8) 5.8 (4.1-8.7) 
Time from biopsy to initial treatment         
median, range (months) 1 (0-5) 1 (0-7) 0.8 (0-7.2) 0.7 (0-4) 
Baseline characteristics         
Age > 60 years 47/134 (35) 51/172 (30) 76/186 (41) 38/102 (37) 
Male sex 68/134 (51) 84/172 (49) 109/186 (59) 44/102 (43) 
Ann Arbor stage III/IV 123/134 (92) 158/172 (92) 149/184 (81) 77/102 (75) 
ECOG PS ≥ 1 43/134 (32) 45/172 (26) 71/185 (38) 15/101 (15) 
B symptoms present 30/134 (22) 54/172 (31) 38/184 (21) 16/101 (16) 
Bone Marrow involvement 83/129 (64) 100/168 (60) 87/169 (51) 59/102 (58) 
Elevated LDH 43/134 (32) 57/171 (33) 59/160 (37) 25/95 (26) 
Hemoglobin level < 12 g/dL 29/134 (22) 32/172 (19) 33/169 (20) 18/94 (19) 
Elevated β2-microglobulin 81/128 (63) 93/159 (58) 31/43 (72) 49/92 (53) 
FLIPI score          
0-1 risk factors 23/134 (17) 41/171 (24) 51/186 (27) 38/96 (40) 
2 risk factors 53/134 (40) 56/171 (33) 62/186 (33) 32/96 (33) 
3-5 risk factors 58/134 (43) 74/171 (43) 73/186 (39) 26/96 (27) 
Histological grade         
1-2 113/134 (84) 132/172 (77) 123/186 (66) 64/102 (63) 
3A 12/134 (9) 22/172 (13) 63/186 (34) 28/102 (27) 
Undetermined/other** 9/134 (7) 18/172 (10) 0 10/102 (10) 
Induction regimen         
R-CHOP 128/134 (96) 157/172 (91) 96/186 (52) 102/102 (100) 
R-CVP 6/134 (4) 15/172 (9) 59/186 (32) 0 
R-Bendamustine 0 0 29/186 (16) 0 
other 0 0 2/186 (1) 0 
Maintenance regimen         
No 76/134 (57) 96/172 (56) 152/186 (82) 59/102 (58) 
Yes 58/134 (43) 76/172 (55) 34/186 (18) 43/102 (42) 
Rituximab 58/58 (100) 76/76 (100) 34/34 (100) 41/43 (95) 
Ibritumomab-tiotexan 0 0 0 2/43 (5) 
 
Table 1
  high-risk low-risk   
  N=122 N=338 P-value 
  no./total no. (%)* no./total no. (%)*   
Cohort       
1 = PRIMA trial 59/122 (48) 113/338 (33) 
  2 = UI/MC - SPORE cohort 42/122 (34) 144/338 (43) 
3 = BCN 21/122 (17) 81/338 (24) 
Baseline characteristics       
Age > 60 years 31/122 (25) 134/338 (40) 0.0050 
Male sex 69/122 (57) 168/338 (50) 0.194 
Ann Arbor stage III/IV 111/120 (93) 273/338 (81) 0.0027 
ECOG PS ≥ 1 45/121 (37) 86/337 (26) 0.015 
B symptoms present 41/121 (34) 67/336 (20) 0.0080 
Bone Marrow involvement 95/116 (82) 152/324 (47) <0.0001 
Elevated LDH 42/111 (38) 99/315 (31) 0.217 
Hemoglobin level < 12 g/dL 28/114 (25) 55/321 (17) 0.083 
Elevated β2-microglobulin 53/80 (66) 120/214 (56) 0.115 
FLIPI score        
0-1 risk factors 19/120 (16) 111/333 (33)  
0.0006 
 
2 risk factors 42/120 (35) 108/333 (32) 
3-5 risk factors 59/120 (49) 114/333 (34) 
Histological grade     
 
1-2 102/122 (84) 217/338 (64)  
0.0004 
 
3A 16/122 (13) 97/338 (29) 
Undetermined/other** 4/122 (3) 24/338 (7) 
Induction regimen       




R-CVP 21/122 (17) 53/338 (16) 
R-Bendamustine 10/122 (8) 19/338 (6) 
other 1/122 (1) 1/338 (0) 
Maintenance regimen       
No 79/122 (65) 228/338 (67) 
0.587 
Yes 43/122 (35) 110/338 (33) 
 
Table 2
   Progression-Free Survival Multivariate Cox model 
Cohort Risk group n (%) Median (yr)  [95%CI] 2 yr (%) [95%CI] 5 yr (%) [95%CI] HR [95%CI] 
1 (Prima) 
n=172 
high-risk 59 (34) 2.9 [2.4-5.8] 66 [54-79] 37 [27-52] 
2.57 [1.65-4.01] 
low-risk 113 (66) NR [NR-NR] 83 [76-90] 68 [59-77] 
2 (UI/MC) 
n=186 
high-risk 42 (23) 3.1 [1.4-5.6] 55 [41-72] 34 [21-55] 
2.12 [1.32-3.39] 
low-risk 144 (77) NR [6.6-NR] 79 [73-86] 62 [54-71] 
3 (BCN) 
n=102 
high-risk 21 (21) 4.3 [1.3-NR] 67 [49-90] 42 [24-73] 
2.11 [1.01-4.41] 
low-risk 81 (79) 10.8 [10.1-NR] 80 [72-89] 70 [61-81] 
All 
n=460 
high-risk 122 (27) 3.1 [2.4-4.8] 62 [54-71] 37 [29-48] 
2.30 [1.72-3.07] 
low-risk 338 (73) 10.8 [10.1-NR] 81 [76-85] 66 [61-71] 
      
Univariate Cox model 
Low 
n=130 
high-risk 19 (15) NR [2.8-NR] 79 [63-100] 57 [39-85] 
2.31 [1.03-5.18] 
low-risk 111 (85) NR [NR-NR] 88 [83-94] 81 [74-89] 
Int 
n=150 
high-risk 42 (28) 4.8 [2.9-NR] 74 [61-88] 45 [31-65] 
1.68 [1.02-2.77] 
low-risk 108 (72) NR [6-NR] 81 [74-89] 60 [52-71] 
High 
n=173 
high-risk 59 (34) 2.1 [1.4-4.5] 50 [39-65] 26 [17-41] 
2.37 [1.58-3.56] 
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